Results 261 to 270 of about 147,468 (308)
Some of the next articles are maybe not open access.
Digestive Diseases and Sciences, 2022
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years ...
Mahak Chauhan +2 more
openaire +2 more sources
Nature Reviews Gastroenterology and Hepatology, 2013
NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty liver to NASH. Although the prevalence of NAFLD is increasing globally, and it is set to become the predominant cause of chronic liver disease in many parts of the world, the
Rohit Loomba, Arun J Sanyal
exaly +3 more sources
NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty liver to NASH. Although the prevalence of NAFLD is increasing globally, and it is set to become the predominant cause of chronic liver disease in many parts of the world, the
Rohit Loomba, Arun J Sanyal
exaly +3 more sources
Autophagy, NAFLD and NAFLD-Related HCC
2018Non-alcoholic fatty liver disease (NAFLD) will become a dominant cause of hepatocellular carcinoma (HCC) in the coming decade. Whereas the exact molecular mechanisms underlying the progression from simple steatosis, through steatohepatitis, to HCC remains largely unclear, emerging evidence has supported a central role of defective autophagy in the ...
William K K, Wu +2 more
openaire +2 more sources
Scandinavian Journal of Gastroenterology, 2021
Dear Editor,I have read the research article entitled ‘Etiologies and outcomes of cirrhosis in a large contemporary cohort’ by Hagstrom et al. [1].
openaire +2 more sources
Dear Editor,I have read the research article entitled ‘Etiologies and outcomes of cirrhosis in a large contemporary cohort’ by Hagstrom et al. [1].
openaire +2 more sources
Nature Reviews Gastroenterology and Hepatology, 2016
The liver constitutes a key organ in systemic metabolism, contributing substantially to the development of insulin resistance and type 2 diabetes mellitus (T2DM). The mechanisms underlying these processes are not entirely understood, but involve hepatic fat accumulation, alterations of energy metabolism and inflammatory signals derived from various ...
Herbert Tilg +2 more
exaly +3 more sources
The liver constitutes a key organ in systemic metabolism, contributing substantially to the development of insulin resistance and type 2 diabetes mellitus (T2DM). The mechanisms underlying these processes are not entirely understood, but involve hepatic fat accumulation, alterations of energy metabolism and inflammatory signals derived from various ...
Herbert Tilg +2 more
exaly +3 more sources
Noninvasive evaluation of NAFLD
Nature Reviews Gastroenterology and Hepatology, 2013A common clinical concern in patients with NAFLD is whether they have NASH or simple steatosis and, more importantly, what the stage of fibrosis is and whether the level of fibrosis has increased over time. Such concern is based on the fact that patients with NAFLD with advanced fibrosis are at greatest risk of developing complications of end-stage ...
laurent Castera, Valérie Vilgrain
exaly +3 more sources
Nature Reviews Gastroenterology and Hepatology, 2013
NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority ...
Quentin M Anstee, Frcp
exaly +3 more sources
NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority ...
Quentin M Anstee, Frcp
exaly +3 more sources
2018
Non-alcoholic fatty liver disease (NAFLD) is an increasingly important cause of chronic liver disease globally. Similar to metabolic syndrome and obesity, NAFLD is associated with alternations in the gut microbiota and its related biological pathways. While the exact pathophysiology of NAFLD remains largely unknown, changes in intestinal inflammation ...
Louis H S, Lau, Sunny H, Wong
openaire +2 more sources
Non-alcoholic fatty liver disease (NAFLD) is an increasingly important cause of chronic liver disease globally. Similar to metabolic syndrome and obesity, NAFLD is associated with alternations in the gut microbiota and its related biological pathways. While the exact pathophysiology of NAFLD remains largely unknown, changes in intestinal inflammation ...
Louis H S, Lau, Sunny H, Wong
openaire +2 more sources
Histological Assessment of NAFLD
Digestive Diseases and Sciences, 2016Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of histological lesions ranging from steatosis to a complex pattern with hepatocyte injury and inflammation in an appropriate clinical context. The disease has been artificially dichotomized into NAFL (steatosis) and NASH (steatosis with hepatocellular injury and inflammation), but it is ...
openaire +2 more sources